Our core foundation is in the science and understanding of cell fate control mechanisms. Using this knowledge, we have identified a series of novel targets for potential new cancer treatments. We subsequently have focused our efforts on inhibiting the action of twin proteins p300 and CBP with a small molecule oral drug.

Collaboration has always been at the heart of CellCentric’s approach to research and development. We hold deep relationships with multiple leading centers of excellence, both scientific and clinical. We also engage with patients and patient-focused organizations to better understand the needs and priorities of people living with cancer.